265 related articles for article (PubMed ID: 16256017)
1. Obesity and lipids.
Miller WM; Nori-Janosz KE; Lillystone M; Yanez J; McCullough PA
Curr Cardiol Rep; 2005 Nov; 7(6):465-70. PubMed ID: 16256017
[TBL] [Abstract][Full Text] [Related]
2. Dyslipidemia intervention in metabolic syndrome: emphasis on improving lipids and clinical event reduction.
Lavie CJ; Milani RV; O'Keefe JH
Am J Med Sci; 2011 May; 341(5):388-93. PubMed ID: 21519201
[TBL] [Abstract][Full Text] [Related]
3. Dyslipidemia in the metabolic syndrome in children.
Gidding SS
J Cardiometab Syndr; 2006; 1(4):282-5. PubMed ID: 17679808
[TBL] [Abstract][Full Text] [Related]
4. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
5. [Residual risk of cardiovascular complications and its reduction with a combination of lipid lowering agents].
Soska V
Vnitr Lek; 2011 Mar; 57(3):313-6. PubMed ID: 21495414
[TBL] [Abstract][Full Text] [Related]
6. Pathogenesis and management of the dyslipidemia of the metabolic syndrome.
Raal FJ
Metab Syndr Relat Disord; 2009 Apr; 7(2):83-8. PubMed ID: 19400742
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis.
Lee M; Saver JL; Towfighi A; Chow J; Ovbiagele B
Atherosclerosis; 2011 Aug; 217(2):492-8. PubMed ID: 21592479
[TBL] [Abstract][Full Text] [Related]
8. Lipid triad or atherogenic lipoprotein phenotype: a role in cardiovascular prevention?
Rizzo M; Berneis K
J Atheroscler Thromb; 2005; 12(5):237-9. PubMed ID: 16205019
[TBL] [Abstract][Full Text] [Related]
9. [Dyslipidemia in visceral obesity: pathophysiological mechanisms, clinical implications and therapy].
Zambon A; Marchiori M; Manzato E
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):29S-39S. PubMed ID: 18773749
[TBL] [Abstract][Full Text] [Related]
10. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
[TBL] [Abstract][Full Text] [Related]
11. Control of the overall lipid profile.
Blasco M; Ascaso JF;
Clin Investig Arterioscler; 2019 Dec; 31 Suppl 2():34-41. PubMed ID: 31785850
[TBL] [Abstract][Full Text] [Related]
12. [Fibrates therapy: Rational use fenofibrate 2016. Executive summary].
Brea A; Millán J; Ascaso JF; Blasco M; Díaz A; González-Santos P; Hernández-Mijares A; Mantilla T; Pedro-Botet JC; Pintó X;
Clin Investig Arterioscler; 2016; 28(6):295-301. PubMed ID: 27609708
[TBL] [Abstract][Full Text] [Related]
13. Managing the dyslipidemia of metabolic syndrome: beyond statin therapy.
Jialal I; Smith G
Metab Syndr Relat Disord; 2012 Jun; 10(3):159-60. PubMed ID: 22568574
[No Abstract] [Full Text] [Related]
14. [Diabetic dyslipidaemia and the atherosclerosis].
Márk L; Dani G
Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
[TBL] [Abstract][Full Text] [Related]
15. Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects.
Hernández-Mijares A; Ascaso JF; Blasco M; Brea Á; Díaz Á; Mantilla T; Pedro-Botet J; Pintó X; Millán J;
Clin Investig Arterioscler; 2019; 31(2):75-88. PubMed ID: 30262442
[TBL] [Abstract][Full Text] [Related]
16. Lipid management: maximising reduction of cardiac risk.
Webb J; Gonna H; Ray KK
Clin Med (Lond); 2013 Dec; 13(6):618-20. PubMed ID: 24298114
[No Abstract] [Full Text] [Related]
17. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study.
Halcox JP; Banegas JR; Roy C; Dallongeville J; De Backer G; Guallar E; Perk J; Hajage D; Henriksson KM; Borghi C
BMC Cardiovasc Disord; 2017 Jun; 17(1):160. PubMed ID: 28623902
[TBL] [Abstract][Full Text] [Related]
18. Dyslipidemia in obesity: mechanisms and potential targets.
Klop B; Elte JW; Cabezas MC
Nutrients; 2013 Apr; 5(4):1218-40. PubMed ID: 23584084
[TBL] [Abstract][Full Text] [Related]
19. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
Tenenbaum A; Fisman EZ; Motro M; Adler Y
Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
[TBL] [Abstract][Full Text] [Related]
20. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.
; ;
Atherosclerosis; 2019 Nov; 290():140-205. PubMed ID: 31591002
[No Abstract] [Full Text] [Related]
[Next] [New Search]
